[A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
作者信息
Korolenko V O, Gershanovich M L, Tikhonova V V
出版信息
Vopr Onkol. 2004;50(4):421-5.
PMID:15605764
Abstract
摘要
相似文献
1
2
[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Ai Zheng. 2006 Apr;25(4):486-9.
3
[Clinical trial of the monoclonal antibody drug mabthera (Rituximab) in the treatment of non-Hodgkin lymphoma].
Vopr Onkol. 2003;49(4):459-63.
4
Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old.
Haematologica. 2005 Sep;90(9):1281-3.
5
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
J Clin Oncol. 2007 Feb 20;25(6):e7. doi: 10.1200/JCO.2006.09.0407.
6
[Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Ai Zheng. 2006 Apr;25(4):481-5.
7
[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Ann Med Interne (Paris). 2003 May;154(3):139-47.
8
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy.
Clin Adv Hematol Oncol. 2005 Feb;3(2):136-9; discussion 139-40.
9
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Dtsch Med Wochenschr. 2007 Aug;132(33):1688-91. doi: 10.1055/s-2007-984950.
10
[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Ai Zheng. 2006 Dec;25(12):1543-9.
Zotero 插件